OnKure Therapeutics, Inc.
OKURHealthcare|Biotechnology|US
$2.87
+0.34 (+13.47%)
DCF Value
$4.23
Tangible Book / Share
$3.16
Cash / Share
$3.27
Financials
Financial Snapshot
Market Cap
$116.0M
Enterprise Value
-$34.6M
Revenue (TTM)
$0.00
Net Income (TTM)
-$61.9M
Cash & Investments
$163.3M
Net Cash
$162.5M
Free Cash Flow (TTM)
-$47.9M
Operating CF (TTM)
-$47.9M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$163.3M
Quarterly Burn
$12.0M
Monthly Burn
$4.0M
Est. Runway
~13.6 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $53.6M | $147.7M | $11.5M | $29.9M | $110.8M | $59.0M | $163.3M | |
| Operating Cash Flow | -$18.5M | -$38.0M | -$27.0M | -$34.5M | -$51.1M | -$51.8M | -$47.9M | |
| Free Cash Flow | -$18.6M | -$38.2M | -$28.1M | -$34.8M | -$51.2M | -$51.9M | -$47.9M | |
| Capital Expenditure | -$24.0K | -$198.0K | -$1.1M | -$246.0K | -$52.0K | -$46.0K | -$49.0K | |
| Financing Cash Flow | $47.3M | $132.4M | $26.5M | $53.1M | $116.1M | $163.0K | $140.9M |
R&D Spending
R&D (TTM)
$50.1M
R&D Intensity
—
R&D Growth vs Prior
+3.8%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $15.9M | $28.1M | $25.9M | $32.1M | $43.8M | $48.3M | $50.1M | |
| SG&A | $3.6M | $11.6M | $3.9M | $4.8M | $10.6M | $14.7M | $15.9M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $37.0K | $50.0K | $0.00 | $0.00 | $0.00 | $830.0K | $203.0K | |
| Gross Profit | -$37.0K | -$50.0K | $0.00 | $0.00 | $0.00 | -$830.0K | -$203.0K | |
| R&D | $15.9M | $28.1M | $25.9M | $32.1M | $43.8M | $48.3M | $50.1M | |
| SG&A | $3.6M | $11.6M | $3.9M | $4.8M | $10.6M | $14.7M | $15.9M | |
| Operating Income | -$19.6M | -$39.8M | -$29.8M | -$36.9M | -$54.4M | -$63.0M | -$66.0M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $300.0K | $0.00 | $6.0K | |
| Pretax Income | -$19.5M | -$39.8M | -$29.5M | -$35.3M | -$52.7M | -$59.5M | -$61.9M | |
| Net Income | -$19.5M | -$39.8M | -$29.5M | -$35.3M | -$52.7M | -$59.5M | -$61.9M | |
| EPS (Diluted) | -7.74 | -21.92 | -2.21 | -2.65 | -3.95 | -4.40 | -2.77 | |
| EBITDA | -$19.4M | -$39.7M | -$29.1M | -$34.8M | -$51.7M | -$58.7M | -$61.0M | |
| Shares Out. (M) | 2.51 | 1.81 | 13.34 | 13.34 | 13.34 | 13.52 | 49.93 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53.6M | $124.7M | $11.5M | $29.9M | $110.8M | $59.0M | $151.4M | |
| Short-Term Investments | $0.00 | $23.0M | $0.00 | $0.00 | $0.00 | $0.00 | $11.9M | |
| Total Current Assets | $55.0M | $153.7M | $13.6M | $33.8M | $113.0M | $60.8M | $165.6M | |
| Total Assets | $55.2M | $154.0M | $16.0M | $35.7M | $114.9M | $62.1M | $167.1M | |
| Total Current Liabilities | $4.6M | $6.2M | $5.5M | $7.3M | $10.5M | $5.9M | $8.8M | |
| Long-Term Debt | $92.7M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $97.3M | $6.8M | $70.4M | $137.6M | $11.1M | $5.9M | $9.3M | |
| Stockholders' Equity | -$42.1M | $147.2M | -$54.4M | -$101.8M | $103.8M | $56.2M | $157.7M | |
| Retained Earnings | -$45.0M | -$84.7M | -$57.1M | -$102.1M | -$154.7M | -$214.2M | -$262.6M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.5M | -$38.0M | -$27.0M | -$34.5M | -$51.1M | -$51.8M | -$47.9M | |
| Capital Expenditure | -$24.0K | -$198.0K | -$1.1M | -$246.0K | -$52.0K | -$46.0K | -$49.0K | |
| Free Cash Flow | -$18.6M | -$38.2M | -$28.1M | -$34.8M | -$51.2M | -$51.9M | -$47.9M | |
| Investing Cash Flow | $7.4M | -$23.4M | -$1.1M | -$246.0K | $15.9M | -$46.0K | -$11.9M | |
| Financing Cash Flow | $47.3M | $132.4M | $26.5M | $53.1M | $116.1M | $163.0K | $140.9M | |
| Issuance of Stock | $47.3M | $132.4M | $340.0K | $65.0K | $58.9M | $203.0K | $150.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$10.1M | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $6.0M | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $48.0K | $199.0K | $4.5M | $11.6M | $12.3M | |
| Net Change in Cash | $36.1M | $71.0M | -$1.6M | $18.3M | $80.9M | -$51.7M | $81.1M |
Dilution Tracker
Shares outstanding grew 437.5% over 5 years — significant dilution
Shares Outstanding
40M
5-Year Share Growth
+437.5%
Stock Issuance (TTM)
$150.4M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 2.51 | 1.81 | 13.34 | 13.34 | 13.34 | 13.52 | 49.93 | |
| Change vs Prior % | — | -27.9% | 635.2% | 0.0% | 0.0% | 1.3% | 269.4% | |
| Stock Issuance | $47.3M | $132.4M | $340.0K | $65.0K | $58.9M | $203.0K | $150.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$10.1M | |
| Stock Based Comp. | $0.00 | $0.00 | $48.0K | $199.0K | $4.5M | $11.6M | $12.3M |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| ROE % | 46.2% | -27.0% | 54.2% | 34.7% | -50.7% | -105.9% | -43.4% | |
| ROA % | -35.2% | -25.8% | -184.5% | -98.8% | -45.8% | -95.8% | -37.0% | |
| ROIC % | -38.6% | -26.9% | -280.6% | -128.9% | -51.8% | -110.9% | -41.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -35.1% | 100.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -103.7% | 25.2% | -24.1% | -47.3% | -15.7% | |
| Net Income | 0.0% | -104.3% | 25.8% | -19.6% | -49.2% | -13.0% | |
| EPS (Diluted) | 0.0% | -183.2% | 89.9% | -19.9% | -49.1% | -11.4% | |
| Operating Cash Flow | 0.0% | -104.9% | 29.0% | -28.2% | -48.0% | -1.4% | |
| Free Cash Flow | 0.0% | -105.7% | 26.4% | -23.9% | -47.1% | -1.4% | |
| R&D Expense | 0.0% | 76.8% | -8.0% | 24.2% | 36.4% | 10.2% | |
| SG&A Expense | 0.0% | 222.9% | -66.5% | 23.4% | 119.8% | 38.7% | |
| Total Assets | 0.0% | 178.9% | -89.6% | 123.4% | 221.6% | -45.9% | |
| Book Value / Share | 0.0% | 584.5% | -105.0% | -87.1% | 202.0% | -46.6% | |
| Debt | 0.0% | -100.0% | 0.0% | 5.8% | 61.0% | -49.4% | |
| Diluted Shares | 0.0% | -27.9% | 635.2% | 0.0% | 0.0% | 1.3% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.91
10Y Low / Med / High0.70 / 1.05 / 1.10
EV/EBITDA0.57
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$4.23
Tangible Book / Share
$3.16
Net Current Assets / Share
$3.86
Graham Net-Net
$3.08
Cash / Share
$3.27
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -19.38 | -3.90 | -10.54 | -6.04 | -2.18 | -0.66 | -1.03 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -8.96 | 1.05 | -5.71 | -2.10 | 1.10 | 0.70 | 0.91 | |
| EV/EBITDA | -21.43 | -0.77 | -10.30 | -5.30 | -0.10 | 0.33 | 0.57 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
5.16
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $166.7K | $666.7K | $2.0M |
| Net Income | -$24.8M | -$21.4M | -$19.1M |
| EPS | $-1.84 | $-1.58 | $-1.41 |
| # Analysts (EPS) | 3 | 2 | 2 |